What does Oryzon Genomics’ U.S. Notice of Allowance cover?

The allowed claims cover the use of LSD1 inhibitors to treat non-aggressive symptoms of borderline personality disorder. Oryzon said this complements its patent portfolio covering aggression.

Has Oryzon Genomics received a granted U.S. patent for vafidemstat?

No; the announcement concerns a Notice of Allowance for U.S. patent application US 17/439,575. Oryzon said the U.S. patent is expected to remain in force until at least 2040 once granted, excluding any potential patent term adjustments or extensions.

How long is Oryzon Genomics’ U.S. vafidemstat patent expected to remain in force?

Oryzon said the U.S. patent is expected to remain in force until at least 2040 once granted. This excludes any potential patent term adjustments or extensions.

What other intellectual property does Oryzon Genomics hold for vafidemstat?

Oryzon said it holds another patent family covering vafidemstat for the treatment of aggression and social withdrawal, alongside other patents covering its use for central nervous system disorders. Patents in this family have been granted or allowed in Australia, Canada, Europe, Hong Kong, Israel, Japan, South Korea, Malaysia, the Philippines and Russia, with additional applications pending in other jurisdictions.

How long are Oryzon Genomics’ patents covering aggression and social withdrawal expected to remain in force?

Oryzon said these patents are expected to remain in force until at least 2038. The company excluded any potential patent term extensions from that expectation.

How does Oryzon Genomics describe the significance of the U.S. Notice of Allowance?

Neus Virgili, Oryzon’s Chief IP Officer, said the Notice of Allowance reinforces the company’s intellectual property position for vafidemstat in borderline personality disorder and supports its long-term development and commercial potential in an area of significant unmet medical need.

What does Oryzon Genomics do and where is its security identified?

Oryzon Genomics describes itself as a clinical-stage biopharmaceutical company focused on epigenetics. The announcement identifies the company by ISIN Code ES0167733015 and the symbol ORY.

Home
News Intelligence
Oryzon Genomics S.A.
Oryzon reports U.S. Notice of Allowance for vafidemstat patent application

Back to all Oryzon Genomics S.A. press releases

Oryzon Genomics S.A.

BME:ORY
OTC PINK:ORYZF

Oryzon reports U.S. Notice of Allowance for vafidemstat patent application

Q: What is vafidemstat and what is Oryzon Genomics developing it for?

Vafidemstat is Oryzon’s LSD1 inhibitor in clinical development for the treatment of psychiatric disorders, including borderline personality disorder. The company also holds patents covering its use for other central nervous system disorders.

Q: In which countries has Oryzon Genomics obtained or been allowed corresponding patents for vafidemstat and borderline personality disorder?

Oryzon said corresponding patents have been granted or allowed in Australia, Europe, Japan, Mexico, Russia, Singapore and South Africa. Additional applications are pending in other jurisdictions.

Published Wednesday, 25 March 2026

Get alerts

Plain English summaries when Oryzon Genomics S.A. announces news.

At a glance

Company: Oryzon Genomics S.A.
Listings: BME:ORY, OTC PINK:ORYZF
Announcement type: Regulatory approval
Published: Wednesday, 25 March 2026
Source announcement: oryzon.com

Key figures
Measure	Figure
Patent term	until at least 2040

Figures are quoted from this announcement and selected automatically.

FAQSIR Generated from this announcement View original release below for safe harbor and regulatory notices

Announcement Summary

On March 25, 2026, Oryzon Genomics, S.A. (ORY) announced a U.S. Notice of Allowance for its vafidemstat patent application.

USPTO issued a Notice for application US 17/439,575, covering LSD1 inhibitors for non-aggressive BPD symptoms.
Allowed claims cover LSD1 inhibitors for non-aggressive BPD symptoms.
If granted, U.S. patent expected in force until at least 2040, excluding potential adjustments/extensions.

Corresponding patents are granted/allowed in Australia, Europe, Japan, Mexico, Russia, Singapore, and South Africa.

Investor FAQs

Oryzon Genomics announced that the United States Patent and Trademark Office had issued a Notice of Allowance for patent application US 17/439,575, entitled “Methods of treating borderline personality disorder”. The application relates to vafidemstat, Oryzon’s LSD1 inhibitor in clinical development for psychiatric disorders including borderline personality disorder.

Source announcement

Company: Oryzon Genomics S.A.
Title: ORYZON strengthens vafidemstat patent portfolio with U.S. Notice of Allowance
Published: Wednesday, 25 March 2026
Source site: oryzon.com

Read the source announcement on oryzon.com

FAQSIR's summary and investor FAQs are generated by AI from the text of this announcement alone, without information from other sources.

Figures, forecasts and other claims are the announcement's, not FAQSIR's. FAQSIR does not independently verify them.

Read the original press release

Full text as published, unedited.

Loading the original release…

Important Notice And Disclaimer

This article was generated by an artificial intelligence system from an announcement published by the issuer. It has not been independently researched, verified, or edited by a journalist, and no person holds editorial responsibility for its wording.

The issuer named in this article has not paid for this page and has no commercial relationship with its publisher. This is an unpaid evaluation preview produced from announcements the issuer published publicly, and it is not independent editorial coverage.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Ask about this announcement

Answers drawn only from this announcement

Reading the announcement…